Indirect Comparisons of Efficacy of Zanubrutinib Versus Orelabrutinib in Patients with R/R MCL: An Extended Follow-up Analysis.

Adv Ther · 2025 · PMC12085368 · PMID 40317419

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a favorable trendno p-value reported

As a result of the very limited number of OS events, the analysis of OS was not powered enough to detect a statistical meaningful difference between these two groups but there is a favorable trend on OS towards zanubrutinib over orelabrutinib (HR 0.68).

also in 1,335 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.